Key result
The 2017 ACC/AHA guidelines increased the proportion of individuals eligible for antihypertensive treatment to 40.3% compared to 31.3% under the 2013 ESH/ESC guidelines.
Why the study?
Does the application of the 2017 ACC/AHA hypertension guidelines increase the proportion of individuals eligible for treatment and associated costs compared to the 2013 ESH/ESC guidelines in the Swiss population?
Cross-Sectional (n=4,438)
Does the application of the 2017 ACC/AHA hypertension guidelines increase the proportion of individuals eligible for treatment and associated costs compared to the 2013 ESH/ESC guidelines in the Swiss population?
Implementation of the 2017 ACC/AHA hypertension guidelines in Switzerland would substantially increase the number of individuals eligible for treatment and associated healthcare costs compared to the 2013 ESH/ESC guidelines.
Answers are grounded in this paper and cite their sources.
May increase treatment population substantially; leaves open whether 2017 ACC/AHA thresholds are cost-effective versus prior guidelines.
Background The 2017 ACC/AHA guidelines on hypertension management recommend the introduction of antihypertensive treatment for patients with new stage 1 hypertension thresholds (130-139/80-89 mm Hg) and with a cardiovascular disease or related condition. We compared the Swiss population and economic impact of antihypertensive treatment of the 2017 ACC/AHA guidelines with the 2013 European guidelines. Methods Analyses were based on 4438 participants (aged 45-85 years; 2448 women) of the CoLaus|PsyCoLaus study recruited between 2014-2017. Participants eligible for antihypertensive treatment according to the 2017 ACC/AHA and 2013 European guidelines were sex and age standardised using the Swiss population for 2016. In addition, we estimated the population-wide annual costs of antihypertensive treatment. Results Individuals eligible for antihypertensive treatment were 40.3% (95% confidence interval 38.5-42.1) and 31.3% (29.7-32.9) according to the 2017 ACC/AHA and 2013 European guidelines, respectively. That difference would translate into approximately 250,000 additional individuals eligible for antihypertensive treatment, corresponding to an additional annual cost of 72.5 million CHF (63.0 million EUR). Conclusion The 2017 ACC/AHA guidelines on the management of hypertension substantially increase the number of individuals eligible for antihypertensive treatment compared to the 2013 European guidelines. While implementation of the 2017 ACC/AHA guidelines is expected to lead to cost reduction by preventing cardiovascular diseases, that reduction might be mitigated by the costs incurred by antihypertensive treatments in a larger proportion of the population.
No takes yet. Share an insight, caveat, or question.
Vaucher et al. (2018) conducted a cross-sectional in Hypertension (n=4,438). 2017 ACC/AHA guidelines vs. 2013 ESH/ESC guidelines was evaluated on Proportion of individuals eligible for antihypertensive treatment. The 2017 ACC/AHA guidelines increased the proportion of individuals eligible for antihypertensive treatment to 40.3% compared to 31.3% under the 2013 ESH/ESC guidelines.
Synapse has enriched 10 related papers. Consider them for comparative context: